StocksMedium•16 November 2026•
1 min read
Akeso Stock Declines Following FDA Rejection of Lung Cancer Drug Application
Key Facts
1Akeso shares experienced a sharp decline following the US FDA's rejection of the company's lung cancer treatment license application.
Akeso shares experienced a sharp decline following the US FDA's rejection of the company's lung cancer treatment license application. Investing.com reported that the rejection creates a major regulatory hurdle and delays the potential commercialization of a key pipeline product.
The stock, traded under the ticker 9926.HK, closed at 82.3 dollars on November 13, 2026. During that session, the shares reached a high of 84.55 dollars and a low of 81.55 dollars.